top of page
All Posts


The CGT Strategic Reset: Why Science is Outpacing the Market
We recently marked Rare Disease Day, a vital moment for the community. For those impacted by rare pathologies, the journey is often defined by a grueling "diagnostic odyssey," complex symptom management, and the constant hurdle of managed care coverage.
For many, cell and gene therapy (CGT) represents the ultimate beacon of hope—offering not just chronic disease management, but the potential for curative outcomes.

Tina Witte
Mar 193 min read


Unsupervised AI vs. Verified Intel: The New Battle for Sales Confidence
Let’s be honest: Most battlecards are digital paperweights. They are built with good intentions, filed into a content system, and promptly ignored. But there’s a new twist to this old problem. When a high-stakes deal gets intense, reps aren't just falling back on instinct, they are turning to AI.

Mark Gigliotti
Mar 102 min read


Notes from the UK & EU Offices: Navigating Global Turmoil Through the Synergy of OSINT and HUMINT
We are living through tumultuous times in geopolitics. Old wars are grinding on, whilst new conflicts erupt daily. Across the UK, Europe, and beyond, these conflicts impact local stability, disrupt markets, and combine to create global turmoil that deeply affects people’s lives.

Gordon Donkin
Mar 33 min read
bottom of page